Variations of Immune Infiltrate and Cell Plasticity Markers in Treated Metastatic Melanoma Patients

Inclusion Criteria: * Patient age ≥ 18 * Female patients must agree to the use of 2 methods of contraception. For man one method of contraception is needed if if his partner is in childbearing age throughout the study and for at least 5 months after last study treatment administration. * Patients with metastatic stage III or IV melanoma relapse * Eligible for a melanoma metastatic treatment indicated and administered as part of usual care * Patients must be willing and able to undergo cutaneous tumor biopsies (except on the face and folds or lymph node) according to the study protocol * Patient insured or beneficiary of a health insurance plan * Patient able to provide informed consent and sign approved consent forms to participate in the study * Patient accepting the conservation of biological samples and their use for clinical research including genetic research Exclusion Criteria: * Hematologic tumours under treatment * Patients with a documented history of autoimmune pathology * Ocular melanoma * Persons placed under the safeguard of justice * Use of immunosuppressants including corticosteroids 4 weeks before the inclusion